Type 2 diabetes mellitus in those who are 18 years and above.
Normally 1 OD or the dose adjusted with individual drug.
Mode of action
Brands containing this Ingredient
Drug Index 2.0 is hereOur new update features a more powerful search feature and easier login.
issues? Contact us
today. Contact Us
Mode of Action
Dipeptidyl peptidase 4 [DPP-4] inhibitors act by enhancing the levels of active incretin hormones such as glucagon-like peptide-1 [GLP-1] and glucose-dependent insulinotropic polypeptide [GIP] that are released by the intestine throughout the day and levels increased in response to a meal. Biguanides such as metformin act by decreasing gluconeogenesis and by in-creasing peripheral metabolism of glucose.
General precautions: Data not available for those below 18 yrs.
Precaution in hepatic diseases: Caution required
Precautions in renal diseases: Dose adjustment not required in mild renal impairment. Reduce dose in moderate or severe renal impairment. Avoid in end-stage renal disease requiring hemodialysis.
Allergy to saxagliptin or other dipeptidyl peptidase-4 [DPP4] inhibitors, metformin or any other ingredient of the formulation; type 1 diabetes mellitus; diabetic ketoacidosis.
Acute pancreatitis [like other DPP4 inhibitors]; URTI; UTI; headache; sinusitis; allergic reactions; hypoglycaemia; nausea and vomiting.
DRUG INTERACTION: CYP3A4/5 inducers such as rifampicin, carbamazepine and dexamethasone could decrease plasma concentration of saxagliptin; CYP3A4/5 inhibitors such as ketoconazole and diltiazem could decrease plasma concentration of saxagliptin.